Diminished sensitivity to pain in schizophrenia has been reported since the early works of Bleuler [Bleuler E. Textbook of psychiatry (trans. Brill HA, 1951). New York: Dover Publications; 1911] and Kraepelin [Kraepelin E. Dementia praecox and paraphrenia. Edinburgh, Scotland: E and S Livingstone; 1919]. Over the last decade, experimental studies have measured pain perception in schizophrenia and produced mixed results. This meta-analysis sought to determine if the scientific literature confirms the hypothesized hypoalgesia in schizophrenia. The search was performed with computerised literature databases. A study was retained in the meta-analysis if: (i) it comprised a group of schizophrenia patients, compared to a control group of healthy volunteers; and (ii) pain was measured via experimental procedures (e.g. thermal, electrical, or mechanical stimuli). Using Comprehensive Meta-Analysis-2, effect size estimates of the differences in pain scores (all pain scores derived from all pain tests) between schizophrenia patients and healthy volunteers were calculated. Eleven studies were included in the meta-analysis. For the composite analysis, a positive, moderate, and significant effect size estimate emerged (N=497; Hedges's g=0.437; p=0.005), suggesting that patients with schizophrenia show a diminished response to experimentally-induced pain. Secondary analyses showed that: (i) drug-free patients also have hypoalgesic responses; and that (ii) sensory thresholds are increased in schizophrenia patients. This meta-analysis substantiates the hypothesis of a diminished pain response in schizophrenia. The study also suggests that hypoalgesia in schizophrenia cannot be solely explained by the effects of antipsychotic drugs, and that it may not be a pain-specific blunted response. Further studies are warranted to determine the clinical and biological correlates, and the social and health consequences, of hypoalgesia in schizophrenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pain.2007.11.007 | DOI Listing |
Behav Pharmacol
October 2021
Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Science.
Patients diagnosed with schizophrenia have been reported to exhibit atypically low pain sensitivity and to vary in their experience of chronic pain. To the best of our knowledge, there has yet to be an animal study that provides information concerning the relationship between models of schizophrenia and pain. In the present study, we investigated several distinct nociceptive behaviors in a translational rat model of schizophrenia (0.
View Article and Find Full Text PDFNeurosci Lett
January 2020
Department of Neurology, Faculty of Medicine, University of Szeged, Szeged, Hungary. Electronic address:
Clinical studies have shown that schizophrenia is accompanied by hypoalgesia. Accordingly, we have previously reported that a chronic schizophrenia-related rat substrain (Wisket) showed decreased acute heat pain sensitivity. The aim of the present study was to determine the mechanical pain sensitivity and the effects of opioid ligands in a chronic osteoarthritic pain model generated using Wisket rats.
View Article and Find Full Text PDFRev Med Liege
June 2017
Service de Psychiatrie et Psychologie médicale, CHU de Liège, site Sart Tilman, Liège, Belgique.
Schizophrenia is a complex pathology. Its prevalence reaches almost 1 %. Its semiology can be diversified.
View Article and Find Full Text PDFCase Rep Psychiatry
September 2015
Instituto Nacional de Salud Mental "Honorio Delgado-Hideyo Noguchi", Jr. Eloy Espinoza 709, Urbanización Palao, San Martín de Porres, Lima 31, Peru ; Facultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Avenida Honorio Delgado 430, Urbanización Ingeniería, San Martín de Porres, Lima 31, Peru.
An alleged reduction of sensitivity to pain in people with schizophrenia has been reported, but the nature of this complex phenomenon has not been elucidated yet. Reports of insensitivity to burns from people with schizophrenia are extremely rare. We report the case of a 24-year-old man who set both of his arms on fire during the first break of paranoid schizophrenia.
View Article and Find Full Text PDFBiol Pharm Bull
July 2014
Laboratory of Medicinal Pharmacology, Osaka University Graduate School of Pharmaceutical Sciences.
Alterations in serotonin (5-HT) neurochemistry have been implicated in the etiology of major neuropsychiatric disorders such as anxiety-spectrum disorders, depression, and schizophrenia. The neuromodulatory effects of 5-HT are mediated through 14 receptor subtypes, and those receptors, including the 5-HT1A receptor, are considered to be potential targets for the treatment of psychiatric disorders. We developed the novel 5-HT1A receptor agonist MKC-242 (called osemozotan) and characterized its neurochemical and pharmacological profiles.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!